>> Companies who produce such drugs have almost carte blanche to make any price they want That's not really right since it's not open competition. MHLW sets a

>> Companies who produce such drugs have almost carte blanche to make any price they want That's not really right since it's not open competition. MHLW sets a price for orphan drugs, which all companies must follow. In practice, the Ministry tends to use global prices as baseline in its negotiations with orphan drug suppliers, through their trade group representatives.